Table 1.
Baseline Characteristics of PD-1/PD-L1 Inhibitor-Treated Patients Analyzed for Thyroid Immune-Related Adverse Events (n=325)
| Characteristic | Value |
|---|---|
| Age at PD-1/PD-L1 inhibitor initiation, yr | 67.2±10.6 |
|
| |
| Female sex | 94 (28.9) |
|
| |
| PD-1 inhibitor | |
| Pembrolizumab | 145 (44.6) |
| Nivolumab | 117 (36.0) |
|
| |
| PD-L1 inhibitor | |
| Durvalumab | 45 (13.8) |
| Atezolizumab | 18 (5.5) |
|
| |
| Type of cancer | |
| Lung cancer | 184 (56.6) |
| Melanoma | 39 (12.0) |
| Renal cell carcinoma | 23 (7.1) |
| Biliary cancer | 19 (5.8) |
| Hepatocellular carcinoma | 16 (1.9) |
| Bladder cancer | 10 (3.1) |
| Gastric cancer | 10 (3.1) |
| Colorectal cancer | 8 (2.5) |
| Oropharyngeal cancer | 6 (1.8) |
| Esophageal cancer | 3 (0.9) |
| Peritoneal carcinomatosis | 2 (0.6) |
| Thymic cancer | 1 (0.3) |
| Nasopharygneal cancer | 1 (0.3) |
| Pancreas cancer | 1 (0.3) |
| Multiple myeloma | 1 (0.3) |
| Canthal cancer | 1 (0.3) |
|
| |
| Duration of follow-up, mo | 5.0 (1.0–9.0) |
|
| |
| Duration of PD-1/PD-L1 inhibitor therapy, mo | 4.0 (1.0–9.0) |
|
| |
| No. of doses of PD-1/PD-L1 inhibitor | 6.0 (3.0–12.0) |
|
| |
| Baseline thyroid function status | |
| Normal | 309 (95.1) |
| Subclinical hypothyroidism | 13 (4.0) |
| Subclinical hyperthyroidism | 3 (0.9) |
Values are expressed as mean±standard deviation, number (%), or median (interquartile range).
PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1.